JAMONY
ESPR

Jacob Asset Management of New York’s Esperion Therapeutics ESPR Stock Holding History

Jacob Asset Management of New York’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$58.8K Buy
+60,000
New +$86.8K 0.08% 63
2021
Q4 		– Sell
-47,534
Closed -$573K – 76
2021
Q3 		$573K Sell
47,534
-16,900
-26% -$246K 0.21% 64
2021
Q2 		$1.36M Hold
64,434
– – 0.45% 53
2021
Q1 		$1.81M Buy
64,434
+33,000
+105% +$974K 0.7% 39
2020
Q4 		$817K Buy
+31,434
New +$942K 0.62% 36

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacob Asset Management of New York's ESPR Position: Q3 2023 in Review

Jacob Asset Management of New York opened a new position in Esperion Therapeutics (ESPR) in Q3 2023: 60,000 shares worth $58.8K. The stake represents 0.08% of the portfolio and ranks #63 among its holdings. This is a return to the name: Jacob Asset Management of New York previously reported a position in ESPR as recently as Q3 2021.

Jacob Asset Management of New York first reported a position in ESPR in Q4 2020 and has held it in 5 quarters since. The position peaked at $1.81M in Q1 2021. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

  • Jacob Asset Management of New York held 60,000 shares of Esperion Therapeutics worth $58.8K as of Q3 2023.
  • Esperion Therapeutics was a new Jacob Asset Management of New York position in Q3 2023.
  • Esperion Therapeutics made up 0.08% of Jacob Asset Management of New York's portfolio in Q3 2023, its #63 holding.
  • Jacob Asset Management of New York first reported a position in Esperion Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Jacob Asset Management of New York's Esperion Therapeutics position peaked at $1.81M in Q1 2021.
  • 122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.